MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17.
   PubMed Web of Science ®Google Scholar
• Chambers LM, Carr C, Freeman L, et al. Does surgical platform impact recurrence and survival? A study of utilization of multiport, single-port, and robotic-assisted laparoscopy in endometrial cancer surgery. Am J Obstet Gynecol. 2019;221(3):243 e241–243 e211.
   Web of Science ®Google Scholar
• Wright JD, Khoury-Collado F, Melamed A. Melamed A: harnessing minimally invasive surgery to improve outcomes in endometrial cancer surgery-the robots are coming. JAMA Surg. 2019;154(6):539.
   PubMed Web of Science ®Google Scholar
• Paulino E, de Melo AC. Adjuvant treatment of endometrial cancer in molecular era: are we ready to move on? Crit Rev Oncol Hematol. 2020;153:103016.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Kanao H, Wang X, et al. Adjuvant treatment of endometrial cancer today. Jpn J Clin Oncol. 2020;50(7):753–765.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–2541.
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–718.
   PubMed Web of Science ®Google Scholar
• Hao Z, Wang P. Lenvatinib in management of solid tumors. Oncologist. 2020;25(2):e302–e310.
   PubMed Web of Science ®Google Scholar
• Ritterhouse LL. Tumor mutational burden. Cancer Cytopathol. 2019;127(12):735–736.
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr., Le DT PD. 1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373(20):1979.
   PubMed Web of Science ®Google Scholar
• Nandakumar V, Mills JR. The now and beyond of tumor mutational burden as a predictor of response to immune checkpoint inhibitors. Clin Chem. 2019;65(2):357.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Jaffee EM: tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–1103.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw. 2019;17(4):302–310.
   PubMed Web of Science ®Google Scholar
• Zhang J, An L, Zhou X, et al. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. Ann Transl Med. 2021;9(7):551.
   PubMed Web of Science ®Google Scholar
• Sevignani C, Calin GA, Siracusa LD, et al. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006;17(3):189–202.
   PubMed Web of Science ®Google Scholar
• Bica-Pop C, Cojocneanu-Petric R, Magdo L, et al. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75(19):3539–3551.
   PubMed Web of Science ®Google Scholar
• Zhao M, Ang L, Huang J, et al. MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis. Tumour Biol. 2017;39(2):1010428317691682.
   Google Scholar
• Wang P, Guan Q, Zhou D, et al. miR-21 inhibitors modulate biological functions of gastric cancer cells via PTEN/PI3K/mTOR pathway. DNA Cell Biol. 2018;37(1):38–45.
   PubMed Web of Science ®Google Scholar
• Hermyt E, Zmarzły N, Grabarek B, et al. Interplay between miRNAs and genes associated with cell proliferation in endometrial cancer. Int J Mol Sci. 2019;20:23.
   Web of Science ®Google Scholar
• Zhao X, Dai L, Yue Q, et al. MiR-195 inhibits migration, invasion and epithelial-mesenchymal transition (EMT) of endometrial carcinoma cells by targeting SOX4. J Biosci. 2019;44:6.
   PubMed Web of Science ®Google Scholar
• Wang P, Zeng Z, Shen X, et al. Identification of a multi-RNA-type-based signature for recurrence-free survival prediction in patients with uterine corpus endometrial carcinoma. DNA Cell Biol. 2020;39(4):615–630.
   PubMed Web of Science ®Google Scholar
• Lv Y, Huang Z, Lin Y, et al. MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma. Oncoimmunology. 2019;8(10):e1629260.
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin Epigenetics. 2019;11(1):123.
   PubMed Web of Science ®Google Scholar
• Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43(W1):W460–466.
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92–105.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Z, Wang Y, et al. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma. Int Immunopharmacol. 2020;88:106884.
   PubMed Web of Science ®Google Scholar
• Garcia C, Ring KL. The role of PD-1 checkpoint inhibition in gynecologic malignancies. Curr Treat Options Oncol. 2018;19(12):70.
   PubMed Web of Science ®Google Scholar
• Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–116.
   PubMed Web of Science ®Google Scholar
• Gillen J, Mills KA, Dvorak J, et al. Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab. Gynecol Oncol Rep. 2019;30:100502.
   PubMed Web of Science ®Google Scholar
• Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, et al.. Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis. J Clin Med. 2020;9:6.
   Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   PubMed Web of Science ®Google Scholar
• Dragomir M, Chen B, Fu X, et al. Key questions about the checkpoint blockade-are microRNAs an answer? Cancer Biol Med. 2018;15(2):103–115.
   PubMed Web of Science ®Google Scholar
• Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16(5):279–294.
   PubMed Web of Science ®Google Scholar
• Peng XX, Yu R, Wu X, et al. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. J Immunother Cancer. 2020;8:1.
   Web of Science ®Google Scholar
• Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–2992.
   PubMed Web of Science ®Google Scholar
• Hu Z, Qu G, Yu X, et al. Acylglycerol kinase maintains metabolic state and immune responses of CD8(+) T cells. Cell Metab. 2019;30(2):290–302 e295.
   PubMed Web of Science ®Google Scholar
• Oh DY, Kwek SS, Raju SS, et al. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181(7):1612–1625 e1613.
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12(2):465–472.
   PubMed Web of Science ®Google Scholar
• Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449–459.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu G, Chu H, et al. Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol Cell. 2018;71(2):201–215 e207.
   PubMed Web of Science ®Google Scholar
• Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res. 2005;11(7):2576–2582.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680.
   PubMed Web of Science ®Google Scholar
• Pavlou MP, Diamandis EP, Blasutig IM. Blasutig IM: the long journey of cancer biomarkers from the bench to the clinic. Clin Chem. 2013;59(1):147–157.
   PubMed Web of Science ®Google Scholar